XD14
XD14 is a potent BET inhibitor with antitumor effect. It binds to BRD2, BRD3, and BRD4 with Kds of 170, 380, and 160 nM, respectively[1].
Product Specifications
CAS Number
[1370888-71-3]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/xd14.html
Purity
95.00
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=C(CC)C(C(C)=O)=C(C)N1)NC2=CC(S(=O)(N(CC)CC)=O)=CC=C2O
Molecular Formula
C20H27N3O5S
Molecular Weight
421.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Schäker-Hübner L, et al. 4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads. J Med Chem. 2021 Oct 14;64 (19) :14620-14646.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD2; BRD3; BRD4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6352364-01 0.1 mL
STX4, ID (STX4, STX4A, Syntaxin-4, Renal carcinoma antigen NY-REN-31) (MaxLight 550)
Ask
View Details